 |
0 Diseases |  |
28 Trials |
|
28 Trials |  |
211 News |  |
| 12345» |
- || NP137 / NETRIS Pharma
Trial completion date, Trial primary completion date, Metastases: LAP-NET1: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Sep 21, 2024
P1, N=52, Recruiting, Sponsor: University Hospital, Grenoble
Trial completion date: Nov 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Mar 2026
- | Journal, Combination therapy, Metastases: Early tumor shrinkage as a prognostic predictor in chemotherapy-na (Pubmed Central) - Sep 7, 2024
Trial completion date: Nov 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Mar 2026 ETS may be a prognostic predictor in chemotherapy-na
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: KEYMAKER-06C: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (clinicaltrials.gov) - Aug 23, 2024
P1/2, N=130, Recruiting, Sponsor: Merck Sharp & Dohme LLC
ETS may be a prognostic predictor in chemotherapy-na Not yet recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS, BMS-986310 / BMS
New P1 trial, Combination therapy, Metastases: Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer (clinicaltrials.gov) - Aug 9, 2024
P1, N=40, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, Metastases: Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Aug 9, 2024
P2, N=41, Active, not recruiting, Sponsor: Institut de Recherches Internationales Servier
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- ||| Opdivo (nivolumab) / BMS, magrolimab (ONO-7913) / Ono Pharma
New P1 trial, Combination therapy, Metastases: ONO-7913-04: The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer (clinicaltrials.gov) - Aug 6, 2024
P1, N=65, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- || Opdivo (nivolumab) / BMS, BMS-986310 / BMS
New P1 trial, Combination therapy, Metastases: ONO-4578-04: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 5, 2024
P1, N=46, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- || Opdivo (nivolumab) / BMS, magrolimab (ONO-7913) / Ono Pharma
New P1 trial, Combination therapy, Metastases: An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 1, 2024
P1, N=32, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- | Khapzory (levoleucovorin) / Aurobindo
Preclinical, Journal: In vitro compatibility of admixture solutions of 5-fluorouracil and khapzory (disodium levofolinate) in a single infusion bag. (Pubmed Central) - Jul 27, 2024
Combining 5-FU and disodium levoleucovorin in admixture IV bags eliminates the risk of catheter occlusion associated with calcium-based levoleucovorin formulations. This approach offers a more favorable operational and safety profile, enhancing convenience for patients and cost-efficiency for institutions.
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Phase classification, Combination therapy, Monotherapy: A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) (clinicaltrials.gov) - Jun 26, 2024
P1/2, N=130, Recruiting, Sponsor: Merck Sharp & Dohme LLC
This approach offers a more favorable operational and safety profile, enhancing convenience for patients and cost-efficiency for institutions. Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2
- |||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Metastases: KEYMAKER-06C: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (clinicaltrials.gov) - Jun 23, 2024
P1/2, N=130, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
New P1/2 trial, New P2 trial, Combination therapy, Monotherapy: A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) (clinicaltrials.gov) - May 24, 2024
P2, N=130, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- | levoleucovorin calcium / Generic mfg.
Journal: Levoleucovorin inhibits LOXL2 (lysyl oxidase like-2) to control breast cancer proliferation: a repurposing approach. (Pubmed Central) - May 19, 2024
Levoleucovorin controlled cell proliferations in MDM-MB 231 and MCF-7 cells with GI50 values of 55.91 ?M and 79.20 ?M respectively. Further, a dose dependent inhibition of cancer cell migration was noted along with apoptosis induction in these cells with levoleucovorin treatment.Communicated by Ramaswamy H. Sarma.
- || Tyvyt (sintilimab) / Innovent Biologics
P2 data, Journal, Combination therapy, Metastases: Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study. (Pubmed Central) - Apr 26, 2024
Further, a dose dependent inhibition of cancer cell migration was noted along with apoptosis induction in these cells with levoleucovorin treatment.Communicated by Ramaswamy H. Sarma. The study demonstrated an encouraging efficacy and manageable safety profile of neoadjuvant sintilimab plus FLOT in HER2-negative locally advanced G/GEJ cancer, which suggested a potential therapeutic option for this population.
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: NuTide:302: A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (clinicaltrials.gov) - Apr 3, 2024
P1/2, N=107, Completed, Sponsor: NuCana plc
The study demonstrated an encouraging efficacy and manageable safety profile of neoadjuvant sintilimab plus FLOT in HER2-negative locally advanced G/GEJ cancer, which suggested a potential therapeutic option for this population. Recruiting --> Completed | N=225 --> 107 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Enrollment closed, Combination therapy, Metastases: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov) - Apr 3, 2024
P2, N=182, Active, not recruiting, Sponsor: NuCana plc
Recruiting --> Completed | N=225 --> 107 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024 Recruiting --> Active, not recruiting
- ||| Lytgobi (futibatinib) / Otsuka
Enrollment change, Combination therapy: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (clinicaltrials.gov) - Mar 2, 2024
P2, N=66, Recruiting, Sponsor: Taiho Oncology, Inc.
Recruiting --> Active, not recruiting N=26 --> 66
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov) - Feb 23, 2024
P2, N=171, Recruiting, Sponsor: NuCana plc
N=26 --> 66 Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Sep 2024
- || Avastin (bevacizumab) / Roche
Trial completion: CLIMB: Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab (clinicaltrials.gov) - Jan 31, 2024
P2, N=20, Completed, Sponsor: Asan Medical Center
Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Sep 2024 Active, not recruiting --> Completed
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Jan 26, 2024
P2, N=41, Not yet recruiting, Sponsor: Institut de Recherches Internationales Servier
- ||| NP137 / NETRIS Pharma
Enrollment open, Trial completion date, Metastases: LAP-NET1: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Dec 18, 2023
P1, N=52, Recruiting, Sponsor: University Hospital, Grenoble
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Nov 2025
- Tevimbra (tislelizumab) / BeiGene
Tislelizumab combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Preliminary results of a single-arm, open-label phase I/II trial (SYLT-023). (Poster Bd # F11) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_215;
P1/2
A phase II study at the RP2D is ongoing. Clinical trial information: NCT05319639.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204). (Poster Bd # N3) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_121;
JCOG2204 is a multi-center, randomized phase II trial comparing neoadjuvant chemotherapy with FLOT (5-fluorouracil/levofolinate/oxaliplatin/docetaxel) versus DOS for resectable type 4 and large type 3 GC...Enrollment in JCOG2204 begun on 14th July, 2023 and clinical trial information is available in Japan Registry of Clinical Trials (jRCTs031230231). Clinical trial information: jRCTs031230231.
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial completion date, Trial primary completion date, Metastases: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-na (clinicaltrials.gov) - Dec 5, 2023
P=N/A, N=757, Active, not recruiting, Sponsor: Takeda
Clinical trial information: jRCTs031230231. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- | Avastin (bevacizumab) / Roche, Kaitanni (cadonilimab) / Akesobio
Enrollment open, Trial initiation date, Combination therapy, Metastases: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer (clinicaltrials.gov) - Nov 15, 2023
P2, N=20, Recruiting, Sponsor: Fujian Cancer Hospital
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 Not yet recruiting --> Recruiting | Initiation date: May 2023 --> Nov 2023
- | Cyramza (ramucirumab) / Eli Lilly
Journal, Metastases: Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16. (Pubmed Central) - Oct 30, 2023
Our study demonstrated prospectively that RAM plus FOLFIRI is an effective second-line treatment after anti-EGFR antibody-containing first-line therapy in RAS wild-type and left-sided mCRC. Furthermore, the results were similar for patients who were previously treated with triplet regimen.
- | leucovorin calcium / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Oct 25, 2023
P2, N=134, Recruiting, Sponsor: Southwest Autism Research & Resource Center
Furthermore, the results were similar for patients who were previously treated with triplet regimen. Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025
- | leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) - Oct 25, 2023
P2, N=80, Recruiting, Sponsor: Southwest Autism Research & Resource Center
Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025 Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025
- | leucovorin calcium / Generic mfg.
Enrollment open: Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium (clinicaltrials.gov) - Oct 25, 2023
P2, N=80, Recruiting, Sponsor: Southwest Autism Research & Resource Center
Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025 Active, not recruiting --> Recruiting
- | Journal: Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy. (Pubmed Central) - Oct 23, 2023
This is the first report that posterior reversible encephalopathy syndrome is caused by a thrombocytopenia regimen, and our case highlights the pathogenic role of a thrombocytopenia regimen in posterior reversible encephalopathy syndrome. However, the association between the thrombocytopenia regimen and previous fluorouracil, leucovorin, oxaliplatin, and docetaxel regimens needs further study.
- ||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Trial completion date, Combination therapy, Metastases: Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) (clinicaltrials.gov) - Oct 19, 2023
P3, N=335, Completed, Sponsor: Merck Sharp & Dohme LLC
However, the association between the thrombocytopenia regimen and previous fluorouracil, leucovorin, oxaliplatin, and docetaxel regimens needs further study. Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Oct 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy. (Pubmed Central) - Aug 30, 2023
In 17 cases, the departments for the preparation of cytostatics in the Czech Republic had to accept restrictions on administering the full dose of leucovorin. These restrictions consisted of reducing the dose of the injectable form of leucovorin, changing the chemotherapy regimen, administering the oral form of calcium folinate, forcing a therapeutic break, or a combination of these approaches.
- || Lytgobi (futibatinib) / Otsuka
Enrollment open, Combination therapy: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (clinicaltrials.gov) - Aug 8, 2023
P2, N=26, Recruiting, Sponsor: Taiho Oncology, Inc.
These restrictions consisted of reducing the dose of the injectable form of leucovorin, changing the chemotherapy regimen, administering the oral form of calcium folinate, forcing a therapeutic break, or a combination of these approaches. Not yet recruiting --> Recruiting
- || Lytgobi (futibatinib) / Otsuka
New P2 trial, Combination therapy: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (clinicaltrials.gov) - Jul 14, 2023
P2, N=26, Not yet recruiting, Sponsor: Taiho Oncology, Inc.
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial completion date, Trial primary completion date, Combination therapy: NuTide:302: A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (clinicaltrials.gov) - Jun 29, 2023
P1/2, N=225, Recruiting, Sponsor: NuCana plc
Not yet recruiting --> Recruiting Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Nov 2023
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Enrollment open, Combination therapy, Metastases: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Jun 23, 2023
P1/2, N=91, Recruiting, Sponsor: NuCana plc
Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Nov 2023 Not yet recruiting --> Recruiting
- ||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Avastin (bevacizumab) / Roche
Journal, Adverse events, Real-world evidence, Real-world: Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database. (Pubmed Central) - Jun 14, 2023
Hyperammonemia cases were more likely to be reported with intravenous fluorouracil than orally administered fluoropyrimidines. Fluoropyrimidines might interact with CKD in hyperammonemia cases.
- | leucovorin calcium / Generic mfg.
Enrollment open: Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) - Jun 1, 2023
P2, N=80, Recruiting, Sponsor: Rossignol Medical Center
Fluoropyrimidines might interact with CKD in hyperammonemia cases. Active, not recruiting --> Recruiting
- ||| zolbetuximab (IMAB362) / Astellas
P3 data, Journal, Metastases: Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. (Pubmed Central) - May 22, 2023
P3
Targeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Zolbetuximab plus mFOLFOX6 might represent a new first-line treatment in these patients.
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial initiation date, Combination therapy, Metastases: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov) - May 6, 2023
P2, N=171, Recruiting, Sponsor: NuCana plc
Zolbetuximab plus mFOLFOX6 might represent a new first-line treatment in these patients. Initiation date: Jan 2023 --> Apr 2023
- | Avastin (bevacizumab) / Roche, Kaitanni (cadonilimab) / Akesobio
New P2 trial, Combination therapy, Metastases: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer (clinicaltrials.gov) - May 3, 2023
P2, N=20, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- Avastin (bevacizumab) / Roche
A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study. (On Demand | Hall A; Poster Bd # 249) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3068;
This regimen maybe a useful as second-line treatment option in such patients. Clinical trial information: jRCTs071190003.
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial completion date, Trial primary completion date, Metastases: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-na (clinicaltrials.gov) - Apr 26, 2023
P3, N=757, Active, not recruiting, Sponsor: Takeda
Clinical trial information: jRCTs071190003. Trial completion date: Apr 2023 --> Mar 2024 | Trial primary completion date: Apr 2023 --> Mar 2024
- |||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial primary completion date, Combination therapy, Metastases: Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) (clinicaltrials.gov) - Apr 6, 2023
P3, N=335, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Apr 2023 --> Mar 2024 | Trial primary completion date: Apr 2023 --> Mar 2024 Trial primary completion date: Jul 2024 --> Mar 2023
- | levoleucovorin calcium / Generic mfg.
Journal: Three-Period Bioequivalence Study of Sodium Levofolinate Injection With Calcium Levofolinate for Injection and Sodium Folinate for Injection in Healthy Chinese Subjects. (Pubmed Central) - Apr 4, 2023
No serious AEs or unexpected serious adverse reactions were observed. Sodium levofolinate was bioequivalent to calcium levofolinate and sodium folinate in Chinese subjects, and the 3 preparations were all well tolerated.
- | leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium (clinicaltrials.gov) - Mar 28, 2023
P2, N=80, Active, not recruiting, Sponsor: Rossignol Medical Center
Sodium levofolinate was bioequivalent to calcium levofolinate and sodium folinate in Chinese subjects, and the 3 preparations were all well tolerated. Trial completion date: Jan 2023 --> Jan 2025 | Trial primary completion date: Jan 2023 --> Jan 2025
- | Tevimbra (tislelizumab) / BeiGene, Novartis
Enrollment open: Phase I Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab (clinicaltrials.gov) - Mar 27, 2023
P1, N=20, Recruiting, Sponsor: Fujian Cancer Hospital
Trial completion date: Jan 2023 --> Jan 2025 | Trial primary completion date: Jan 2023 --> Jan 2025 Not yet recruiting --> Recruiting
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (clinicaltrials.gov) - Mar 20, 2023
P3, N=890, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Avastin (bevacizumab) / Roche
P2 data, Journal, Metastases: Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial. (Pubmed Central) - Mar 4, 2023
P2
The addition of bevacizumab did not seem to increase the benefit of FOLFIRI with regard to overall survival. FOLFIRI could be considered as a standard second-line treatment in patients with gastroenteropancreatic neuroendocrine carcinoma.
- |||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) (clinicaltrials.gov) - Mar 2, 2023
P3, N=335, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
FOLFIRI could be considered as a standard second-line treatment in patients with gastroenteropancreatic neuroendocrine carcinoma. Trial completion date: Jan 2027 --> Jul 2024 | Trial primary completion date: Jan 2027 --> Jul 2024